During Sunday morning’s Prime Time plenary session, two experts will review two of the latest treatment options for erectile dysfunction (ED): plasma-rich platelet therapy and botulinum toxin A.
“Evidence about these treatment modalities is just starting to rise up,” said Serge Carrier, MD, FRCS(C), MMmgt, Chief of Surgical Services at McGill University in Montreal, Canada. “It’s important to have a good discussion to see how these treatments can help our patients and in what context.”
Dr. Carrier will moderate the 15-minute panel discussion Innovative Approaches to Erectile Dysfunction, which will begin at 9 am in the Esplanade Ballroom at Moscone South. Trinity Bivalacqua, MD, PhD, Director of Urologic Oncology at the James Buchanan Brady Urologic Institute, will discuss plasma- rich platelet therapy, and Tom Lue, MD, professor of Urology at the University of California, San Francisco, will discuss botulinum toxin A.
Treatment with platelet-rich plasma involves a blood draw that is treated to separate the patient’s platelets, which are then injected back into the penis. The platelets are then supposed to release proteins and growth factors to stimulate tissue healing. This treatment is available in the Priapus Shot®.
Currently, limited data are available on the use of platelet-rich plasma for treatment of ED.
A small study presented at the 2016 annual meeting of the Sexual Medicine Society of North America indicated that adding platelet-rich plasma to an ED therapy regimen could have a significant effect on ED. The authors of the study reviewed the charts of 11 patients treated with platelet-rich plasma for ED and found that 90 percent had maintained or improved scores on the International Index of Erectile Function (IIEF). Patients reported no adverse events or side effects to the therapy.
Another study presented at the 2018 World Meeting on Sexual Medicine looked at the use of platelet-rich plasma in 124 patients with ED. Patients received 10 mL of Tru platelet-rich plasma penile injections. Full data were obtained for 40 patients and among them was a significant improvement in the mean IIEF score from baseline to posttreatment. The majority of patients reported improved erection hardness and ability to engage in successful intercourse. Again, there were no reported side effects.
Similar to the use of platelet-rich plasma, few clinical data are available on the use of botulinum toxin A in the treatment of ED.
In a small pilot study published in The Journal of Sexual Medicine Ghanem et al tested a single intracavernous injection of botulinum toxin A in 12 patients. The treatment was shown to increase arterial flow and improve Sexual Health Inventory for Men scores at two weeks.
Drs. Bivalacqua and Lue will review these studies as well as all of the latest research on these emerging treatment options.
“I hope attendees leave this session knowing where to place these modalities in their practice,” Dr. Carrier said. “They should be aware that the patient will ask for it in the treatment of erectile dysfunction. Urologists have to know they are coming their way because patients will wonder about these treatments.”